Investigational drug · Phase 2
XC001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Coronary Artery Disease (CAD).
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 12, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "XC001"
First trial start
2025
Aug 27, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "XC001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Coronary Artery Disease (CAD)
Approved drugs for the same conditions: Coronary artery disease and heart attack
Largest trials
Live from ClinicalTrials.gov: studies naming "XC001" as an intervention, largest first.
- Epicardial Delivery of XC001 Gene Therapy to Promote Angiogenesis in CAD Patients Undergoing Treatment With CABGPivotal-lookingNot yet recruiting
XyloCor Therapeutics, Inc.Industry
NCT07118449 · 116 participants (planned) · Start Aug 27, 2025 · Primary completion Dec 30, 2026
Drug: XC001; A195/placebo · For: Coronary Artery Disease (CAD)
Sites: Cincinnati, Ohio
- Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment (The EXACT Trial)Completed
XyloCor Therapeutics, Inc.Industry
NCT04125732 · 41 participants · Start Jan 24, 2020 · Primary completion Jan 31, 2023
Drug: AdVEGFXC1 · For: Coronary Artery Disease; Ischemia; Angina Refractory and 2 more
Sites: Stanford, California; Washington D.C., District of Columbia; Daytona Beach, Florida · 16 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Discovery of Two New Neuroprotective Isocoumarin Dimers From the Dendrobium huoshanense-derived Streptomyces sp. AHMU XC001.
Ding W, Xie C, Wang H, et al. · Chem Biodivers 2025
- A VEGF gene therapy approach for the treatment of patients with coronary artery disease and refractory angina: assessment of clinical development.
Guddeti RR, Wong A, Rudick S, et al. · Expert Opin Investig Drugs 2025
- Angiogenic Gene Therapy for Refractory Angina: Results of the EXACT Phase 2 Trial.
Nakamura K, Henry TD, Traverse JH, et al. · Circ Cardiovasc Interv 2024
- Safety and biodistribution of XC001 (encoberminogene rezmadenovec) gene therapy in rats: a potential therapy for cardiovascular diseases.
Stewart DJ, Gianchetti A, Byrnes D, et al. · Gene Ther 2024
- EXACT Trial: Results of the Phase 1 Dose-Escalation Study.
Povsic TJ, Henry TD, Traverse JH, et al. · Circ Cardiovasc Interv 2023
- Epicardial delivery of XC001 gene therapy for refractory angina coronary treatment (The EXACT Trial): Rationale, design, and clinical considerations.
Povsic TJ, Henry TD, Ohman EM, et al. · Am Heart J 2021
Also in development for Coronary Artery Disease (CAD)
- EA-230hourPhase 31 trial
EBI Anti Sepsis BV · Coronary Artery Disease (CAD), Coronary Artery Bypass Graft Surgery(CABG)
- SRSD107Phase 22 trials
Sirius Therapeutics Co., Ltd. · Venous Thromboembolism, Coronary Artery Disease (CAD), Peripheral Arterial Disease
- A195Phase 21 trial
XyloCor Therapeutics, Inc. · Coronary Artery Disease (CAD)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.